Venn Life Sciences Holdings PLC InnoVenn expands products and first sales in US
April 02 2015 - 2:00AM
RNS Non-Regulatory
TIDMVENN
Venn Life Sciences Holdings PLC
02 April 2015
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
InnoVenn expands its Labskin product line and confirms first
sales to the US
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing clinical trial management and
resourcing solutions to pharmaceutical, biotechnology and medical
device clients, announces that InnoVenn, the skin science division
of Venn, has extended its product line and seen first sales in the
US.
InnoVenn have introduced a new 12 well-plates version of the
research grade human skin equivalent, Labskin. Labskin has
traditionally been produced in 6 well-plate assays with unique
qualities such as its ability to support microflora, improved
barrier function and longer test window, positioning it as a world
leader in the area of skin science research. The 6 well-plate
provides a large area of skin for those requiring easy
manipulation, application and sampling. It is ideally suited to
large scale samples, repeated sampling and application protocols.
In contrast the new 12 well-plates provide the same quality product
but in a smaller format for study designs requiring additional
technical and biological replicates. It allows Labskin to target a
bigger market.
Labskin has established its utility in the cosmetic and
dermatological skin research industries with key opinion leaders
championing it as a viable alternative to testing products on human
or animal skin. The European Union implemented a complete ban on
animal testing for cosmetics in March 2013. This ban has led to the
market seeking out viable and reliable alternatives for a host of
different cosmetic and pharmaceutical products.
InnoVenn has also recently launched its United States service,
shipping to a leading cosmetics, personal care and chemical testing
group in Michigan who are carrying out tests to measure skin
metabolism in different environments.
Commenting on this development Venn CEO, Tony Richardson stated:
"This expansion of InnoVenn's product line illustrates that this
part of the business is growing independently of the CRO business,
which is our strategic plan, allowing InnoVenn to be well
positioned to deliver on the full potential of its technology
portfolio. Labskin continues to break barriers in terms of its
capacity to replicate human skin and colonise microflora and we
look forward to bringing Labskin to a global audience."
Enquiries:
Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Orla McGuinness, Marketing Manager Tel: +33 676931178
Zeus Capital (Nominated Adviser
and Broker)
Ross Andrews/Andrew Jones Tel: 0161 831 1512
Alex Davies Tel: 020 7533 7727
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About InnoVenn
InnoVenn (55.6% owned by Venn) is a market development
accelerator dedicated to rapidly commercialising proven scientific
breakthroughs in the form of products and technologies primarily in
Skin Science. These include Labskin the breakthrough research grade
human skin testing platform as well as the clinically proven
Blemish Control Technology for the professional skincare market.
For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing
clinical trial management solutions and resourcing solutions to
pharmaceutical, biotechnology and medical device organisations.
With dedicated operations in France, Germany, the Netherlands, the
UK and Ireland and Europe wide representation - Venn specialises in
rapid deployment and management of multisite projects. Venn
recently established an innovation division - Innovenn - focused
primarily on breakthrough development opportunities in Skin
Science. For more information, visit www.vennlifesciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEFLFBEZFEBBK
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024